ck-2017357 and Myasthenia-Gravis

ck-2017357 has been researched along with Myasthenia-Gravis* in 2 studies

Trials

1 trial(s) available for ck-2017357 and Myasthenia-Gravis

ArticleYear
A Double-Blinded, Randomized, Placebo-Controlled Trial to Evaluate Efficacy, Safety, and Tolerability of Single Doses of Tirasemtiv in Patients with Acetylcholine Receptor-Binding Antibody-Positive Myasthenia Gravis.
    Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2015, Volume: 12, Issue:2

    Tirasemtiv is a fast skeletal troponin activator that sensitizes the sarcomere to calcium and increases muscle force following subtetanic nerve input. In an animal model of myasthenia gravis (MG), single oral doses of tirasemtiv improved muscle force and reduced fatigability. The purpose of this study was to determine the effect of single doses of tirasemtiv on skeletal muscle function and fatigability in patients with generalized MG. Thirty-two patients with acetylcholine receptor-antibody positive MG and muscle weakness received single doses of tirasemtiv (250 mg or 500 mg) or placebo in a double-blind, randomized treatment sequence with each treatment separated by at least 1 week. Outcome measures included the Quantitative MG Score (QMG), MG Composite, Manual Muscle Testing, and forced vital capacity. At 6 h after dosing, tirasemtiv produced dose-related improvements from baseline in the QMG score (slope: -0.49 QMG point per 250 mg; pā€‰=ā€‰0.02) and in percent predicted forced vital capacity (slope: 2.2% per 250 mg; pā€‰=ā€‰0.04). QMG improved >3 points in twice as many patients after 500 mg tirasemtiv than after placebo. Both doses of tirasemtiv were well tolerated; there were no premature terminations or serious adverse events. The results of this study suggest that tirasemtiv may improve muscle function in MG and will be used to support further development of tirasemtiv in neuromuscular diseases.

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Imidazoles; Male; Middle Aged; Muscle, Skeletal; Myasthenia Gravis; Outcome Assessment, Health Care; Protein Binding; Pyrazines; Receptors, Cholinergic; Young Adult

2015

Other Studies

1 other study(ies) available for ck-2017357 and Myasthenia-Gravis

ArticleYear
Activation of fast skeletal muscle troponin as a potential therapeutic approach for treating neuromuscular diseases.
    Nature medicine, 2012, Feb-19, Volume: 18, Issue:3

    Limited neural input results in muscle weakness in neuromuscular disease because of a reduction in the density of muscle innervation, the rate of neuromuscular junction activation or the efficiency of synaptic transmission. We developed a small-molecule fast-skeletal-troponin activator, CK-2017357, as a means to increase muscle strength by amplifying the response of muscle when neural input is otherwise diminished secondary to neuromuscular disease. Binding selectively to the fast-skeletal-troponin complex, CK-2017357 slows the rate of calcium release from troponin C and sensitizes muscle to calcium. As a consequence, the force-calcium relationship of muscle fibers shifts leftwards, as does the force-frequency relationship of a nerve-muscle pair, so that CK-2017357 increases the production of muscle force in situ at sub-maximal nerve stimulation rates. Notably, we show that sensitization of the fast-skeletal-troponin complex to calcium improves muscle force and grip strength immediately after administration of single doses of CK-2017357 in a model of the neuromuscular disease myasthenia gravis. Troponin activation may provide a new therapeutic approach to improve physical activity in diseases where neuromuscular function is compromised.

    Topics: Adenosine Triphosphatases; Animals; Calcium; Cattle; Humans; Imidazoles; Molecular Targeted Therapy; Muscle Contraction; Muscle Fibers, Skeletal; Muscle, Skeletal; Myasthenia Gravis; Myosins; Neuromuscular Diseases; Pyrazines; Rabbits; Rats; Troponin; Troponin C

2012